Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

New Anticancer Agents: Design, Synthesis and Evaluation.

International journal of molecular sciences·2025

Same author

Interactions with DNA Models of the Oxaliplatin Analog (<i>cis</i>-1,3-DACH)PtCl<sub>2</sub>.

International journal of molecular sciences·2024

Same author

Cyclooxygenase and Cancer: Fundamental Molecular Investigations.

International journal of molecular sciences·2023

Same author

Cisplatin and zoledronic acid: two drugs combined in a Pt(II) complex with potential antitumor activity towards bone tumors and metastases.

Dalton transactions (Cambridge, England : 2003)·2023

Same author

Crystal Structure of the Human Copper Chaperone ATOX1 Bound to Zinc Ion.

Biomolecules·2022

Same author

Improvement of Kiteplatin Efficacy by a Benzoato Pt(IV) Prodrug Suitable for Oral Administration.

International journal of molecular sciences·2022

Search research articles

Related Experiment Video

Updated: Jul 17, 2026

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

Trans-platinum complexes in cancer therapy.

Mauro Coluccia¹, Giovanni Natile

¹Department of Scienze Biomediche e Oncologia Umana, University of Bari, Piazza G. Cesare 11, I-70124 Bari, Italy.

Anti-Cancer Agents in Medicinal Chemistry

|February 3, 2007

Summary

New research shows that modified transplatin compounds can be effective against cisplatin-resistant tumors. These platinum-based drugs overcome inactivity issues by altering DNA binding and stability, offering new hope for cancer treatment.

More Related Videos

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Published on: November 10, 2013

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Related Experiment Videos

Last Updated: Jul 17, 2026

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Published on: November 10, 2013

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Area of Science:

Medicinal Chemistry
Oncology
Biochemistry

Background:

Cisplatin is a cornerstone platinum-based chemotherapy drug.
Cisplatin resistance is a major clinical challenge in cancer treatment.
Transplatin, the trans-isomer of cisplatin, is generally considered inactive against tumors.

Purpose of the Study:

To investigate the potential of transplatin derivatives in overcoming cisplatin resistance.
To explore the mechanisms behind the activity of modified transplatin compounds.
To identify novel platinum-based drugs for refractory cancers.

Main Methods:

Synthesis of novel transplatin derivatives with modified ligands (N-donor heterocycles, aliphatic amines, imino ligands).
In vitro evaluation of tumor cell growth inhibitory potency.
Assessment of activity against cisplatin-refractory/resistant tumor cell lines.
In vivo efficacy studies in relevant animal models.
Mechanistic studies on DNA adduct formation and kinetic stability.

Main Results:

Several transplatin derivatives demonstrated significant in vitro potency against tumor cells.
Some derivatives showed activity against cisplatin-refractory/resistant cell lines.
Certain compounds exhibited notable in vivo antitumor activity.
Ligand modification was shown to reduce kinetic instability and alter DNA adduct profiles.

Conclusions:

Transplatin derivatives, contrary to the parent compound, can possess significant antitumor activity.
Modifications to transplatin ligands can restore efficacy against resistant tumors by altering drug deactivation and DNA interaction.
Further research into these transplatin complexes may lead to clinical development for refractory cancers.